Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data.

ABSTRACT:

Background

Minor histocompatibility antigens (mHA) mediate much of the graft vs. leukemia (GvL) effect and graft vs. host disease (GvHD) in patients who undergo allogeneic stem cell transplantation (SCT). Therapeutic decision making and treatments based upon mHAs will require the evaluation of multiple candidate mHAs and the selection of those with the potential to have the greatest impact on clinical outcomes. We hypothesized that common, immunodominant mHAs, which are presented by HLA-A, B, and C molecules, can mediate clinically significant GvL and/or GvHD, and that these mHAs can be identified through association of genomic data with clinical outcomes.

Methodology/principal findings

Because most mHAs result from donor/recipient cSNP disparities, we genotyped 57 myeloid l

SUBMITTER: Armistead PM 

PROVIDER: S-EPMC3153501 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature